[시장보고서]세계의 바이오베터 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

세계의 바이오베터 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Biobetters Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

상품코드 : 1767780

리서치사 : Persistence Market Research

발행일 : 2025년 07월

페이지 정보 : 영문 180 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,216,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,539,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,273,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

주요 내용

바이오베터 시장 규모 : 711억 달러(2025년)
예측 시장 규모 : 1,230억 달러(2032년)
세계 시장 성장률 : 8.2%(2025-2032년 CAGR)

바이오베터 시장 - 보고서 범위

바이오베터는 기존 생물학적 제제를 개량한 것으로 오리지널 생물학적 제제나 바이오시밀러에 비해 효능, 안전성, 환자 순응도를 높이기 위해 고안된 제품입니다. 바이오베터 시장은 제약사, 생명공학 기업, 의료 서비스 제공업체에게 암, 자가면역질환, 감염성 질환 등 다양한 만성질환 및 복합질환에 대한 첨단 치료 옵션을 제공합니다. 시장 성장의 원동력은 표적 치료에 대한 수요 증가, 단백질 공학 및 약물 전달 기술의 발전, 만성 질환의 전 세계적인 유행입니다.

시장 성장 촉진요인

세계 바이오베터 시장은 임상 프로파일이 개선되고 면역원성이 감소된 생물학적 제제의 채택이 증가하는 등 여러 요인에 의해 주도되고 있습니다. 기존 생물학적 제제의 안전성과 효능을 향상시키는 데 중점을 둔 연구개발에 대한 투자 확대가 시장 확대에 크게 기여하고 있습니다. 또한, 블록버스터 생물학적 제제의 특허 만료가 더 우수한 성능을 가진 대체품으로 바이오베터의 개발을 촉진하고 있습니다. 바이오베터가 기존 생물학적 제제나 바이오시밀러보다 우수하다는 인식이 의료진과 환자들 사이에서 확산되고 있는 것도 시장 성장을 더욱 촉진하고 있습니다.

시장 성장 억제요인

유망한 성장 전망에도 불구하고, 바이오베터 시장은 높은 개발 비용, 복잡한 규제 경로, 긴 승인 절차 등의 문제에 직면해 있습니다. 바이오베터 의약품이 오리지널 의약품보다 안전성과 유효성이 향상되었음을 입증하기 위해서는 대규모 임상시험이 필요하며, 이는 제조업체에 경제적, 시간적 부담이 큽니다. 또한, 각 지역에서의 가격 압박과 상환의 불확실성, 특히 비용에 민감한 신흥 경제국에서 시장 침투를 제한할 수 있습니다.

시장 기회

바이오베터 시장은 첨단 단백질 변형 기술, 새로운 약물 전달 시스템, 바이오마커에 기반한 환자 계층화 등의 기술 혁신으로 인해 큰 성장 기회를 맞이하고 있습니다. 새로운 치료 영역 및 적응증에 대한 바이오베터의 확장은 다각화 및 수익 확대의 가능성을 제공합니다. 제약사, 학계, 위탁개발기관 간의 공동연구는 혁신을 촉진하고 제품 개발을 가속화합니다. 또한, 개인 맞춤형 의료 접근법의 채택이 증가함에 따라 특정 환자의 요구에 맞는 바이오베터에 대한 수요가 증가하고 있습니다.

이 보고서는 세계 바이오베터 시장을 조사했으며, 성장 촉진요인, 동향, 기회, 과제 등 시장 역학에 대한 상세한 분석을 제공합니다.

주요 하이라이트
- 시장 규모와 전년대비 성장
- 절대적 매출 기회
시장 규모 분석과 예측
- 시장 규모 분석(2019년-2024년)
- 현재 시장 규모 분석과 예측(2025년-2032년)
세계의 바이오베터 시장 전망 : 제품 유형
- 서론/주요 조사 결과
- 과거 시장 규모 분석 : 제품 유형별(2019년-2024년)
- 현재 시장 규모 분석과 예측 : 제품 유형별(2025년-2032년)
  - 에리스로포이에틴 바이오베터
  - G-CSF 바이오베터
  - 인터페론 바이오베터
  - 인슐린 바이오베터
  - 단일클론항체 바이오베터
  - 항혈우병 인자
  - 기타
- 시장 매력 분석 : 제품 유형
세계의 바이오베터 시장 전망 : 적응증
- 서론/주요 조사 결과
- 시장 규모 분석 : 적응증별(2019년-2024년)
- 현재 시장 규모 분석과 예측 : 적응증별(2025년-2032년)
  - 당뇨병
  - 암
  - 신장병
  - 신경 퇴행성 질환
  - 유전성 질환(혈우병)
  - 기타
- 시장 매력 분석 : 적응증
세계의 바이오베터 시장 전망 : 투여 경로
- 서론/주요 조사 결과
- 시장 규모 분석 : 투여 경로별(2019년-2024년)
- 현재 시장 규모 분석과 예측 : 투여 경로별(2025년-2032년)
  - 피하
  - 정맥
- 시장 매력 분석 : 투여 경로
세계의 바이오베터 시장 전망 : 유통 채널
- 서론/주요 조사 결과
- 시장 규모 분석 : 유통 채널별(2019년-2024년)
- 현재 시장 규모 분석과 예측 : 유통 채널별(2025년-2032년)
  - 병원 약국
  - 소매 약국
  - 온라인 약국
- 시장 매력 분석 : 유통 채널

제5장 세계의 바이오베터 시장 전망 : 지역

주요 하이라이트
시장 규모 분석 : 지역별(2019년-2024년)
현재 시장 규모 분석과 예측 : 지역별(2025년-2032년)
- 북미
- 유럽
- 동아시아
- 남아시아 및 오세아니아
- 라틴아메리카
- 중동 및 아프리카
시장 매력 분석 : 지역

제6장 북미의 바이오베터 시장 전망

제7장 유럽의 바이오베터 시장 전망

제8장 동아시아의 바이오베터 시장 전망

제9장 남아시아 및 오세아니아의 바이오베터 시장 전망

제10장 라틴아메리카의 바이오베터 시장 전망

제11장 중동 및 아프리카의 바이오베터 시장 전망

제12장 경쟁 구도

시장 점유율 분석(2025년)
시장 구조
- 경쟁 강도 맵 : 시장별
- 경쟁 대시보드
기업 개요(상세 - 개요, 재무, 전략, 최근 발전)
- Amgen Inc.
- F.Hoffmann-La Roche AG
- Merck & Co. Inc.
- Sanofi SA
- SERVIER
- Porton Biopharma Limited
- Eli Lily and Company
- Novo Nordisk A/S
- Biogen Inc.
- CSL Behring GmbH
- Teva Pharmaceutical Industries Ltd.
- Celltrion Healthcare Co., Ltd.

제13장 부록

LSH

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global biobetters market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global biobetters market from 2025 to 2032.

Key Insights:

Biobetters Market Size (2025E): USD 71.1 Billion
Projected Market Value (2032F): USD 123.0 Billion
Global Market Growth Rate (CAGR 2025 to 2032): 8.2%

Biobetters Market - Report Scope:

Biobetters are improved versions of existing biologic drugs, engineered to enhance efficacy, safety, and patient compliance compared to original biologics or biosimilars. The biobetters market caters to pharmaceutical companies, biotechnology firms, and healthcare providers by offering advanced therapeutic options for various chronic and complex diseases, including oncology, autoimmune disorders, and infectious diseases. Market growth is driven by increasing demand for targeted therapies, advancements in protein engineering and drug delivery technologies, and growing prevalence of chronic illnesses worldwide.

Market Growth Drivers:

The global biobetters market is propelled by several key factors, including rising adoption of biologic therapies with improved clinical profiles and reduced immunogenicity. Growing investments in research and development activities focusing on enhancing existing biologic drugs' safety and efficacy contribute significantly to market expansion. Additionally, patent expirations of blockbuster biologics are fueling the development of biobetters as alternatives with better performance characteristics. Increasing awareness among healthcare professionals and patients about the benefits of biobetters over traditional biologics and biosimilars further supports market growth.

Market Restraints:

Despite promising growth prospects, the biobetters market faces challenges related to high development costs, complex regulatory pathways, and lengthy approval processes. The need for extensive clinical trials to demonstrate improved safety and efficacy over originator biologics imposes significant financial and time burdens on manufacturers. Furthermore, pricing pressures and reimbursement uncertainties in various regions may limit market penetration, particularly in cost-sensitive emerging economies.

Market Opportunities:

The biobetters market presents significant growth opportunities driven by technological innovations such as advanced protein modification techniques, novel drug delivery systems, and biomarker-based patient stratification. Expansion of biobetters into new therapeutic areas and indications offers potential for diversification and revenue growth. Collaborations between pharmaceutical companies, academic institutions, and contract research organizations foster innovation and accelerate product development. Moreover, increasing adoption of personalized medicine approaches amplifies demand for biobetters tailored to specific patient needs.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the biobetters market globally?
Which therapeutic areas and drug types are driving biobetter adoption across healthcare settings?
How are technological advancements reshaping the competitive landscape of the biobetters market?
Who are the key players contributing to the biobetters market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global biobetters market?

Competitive Intelligence and Business Strategy:

These companies invest heavily in R&D to develop next-generation biologics with enhanced therapeutic profiles. Partnerships with biotechnology firms and contract development organizations facilitate efficient product development and market entry. Emphasis on clinical trials, regulatory compliance, and patient-centric approaches fosters market growth and improves patient outcomes in the evolving biobetters landscape.

Key Companies Profiled:

Amgen Inc.
F.Hoffmann-La Roche AG
Merck & Co. Inc.
Sanofi SA
SERVIER
Porton Biopharma Limited
Eli Lily and Company
Novo Nordisk A/S
Biogen Inc.
CSL Behring GmbH
Teva Pharmaceutical Industries Ltd.
Celltrion Healthcare Co., Ltd.

Biobetters Market Research Segmentation:

The biobetters market encompasses a diverse range of products, technologies, therapeutic applications, and end-user segments, addressing various chronic and complex disease areas.

By Product Type

Erythropoietin Biobetters
G-CSF Biobetters
Interferon Biobetters
Insulin Biobetters
Monoclonal Antibodies Biobetters
Anti-haemophilic Factor
Others

By Indication

Diabetes
Cancer
Renal Disease
Neurodegenerative Disease
Genetic Disorders (Haemophilia)
Others

By Route of Administration

Subcutaneous
Intravenous

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

North America
Latin America
Europe
East Asia
South Asia & Oceania
The Middle East & Africa

1. Executive Summary

1.1. Global Biobetters Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Regulatory Landscape
3.2. Product Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter's Five Force Analysis

4. Global Biobetters Market Outlook:

4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
4.3. Global Biobetters Market Outlook: Product Type
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019-2024
- 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
  - 4.3.3.1. Erythropoietin Biobetters
  - 4.3.3.2. G-CSF Biobetters
  - 4.3.3.3. Interferon Biobetters
  - 4.3.3.4. Insulin Biobetters
  - 4.3.3.5. Monoclonal Antibodies Biobetters
  - 4.3.3.6. Anti-haemophilic Factor
  - 4.3.3.7. Others
- 4.3.4. Market Attractiveness Analysis: Product Type
4.4. Global Biobetters Market Outlook: Indication
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2024
- 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
  - 4.4.3.1. Diabetes
  - 4.4.3.2. Cancer
  - 4.4.3.3. Renal Disease
  - 4.4.3.4. Neurodegenerative Disease
  - 4.4.3.5. Genetic Disorders (Haemophilia)
  - 4.4.3.6. Others
- 4.4.4. Market Attractiveness Analysis: Indication
4.5. Global Biobetters Market Outlook: Route of Administration
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2024
- 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
  - 4.5.3.1. Subcutaneous
  - 4.5.3.2. Intravenous
- 4.5.4. Market Attractiveness Analysis: Route of Administration
4.6. Global Biobetters Market Outlook: Distribution Channel
- 4.6.1. Introduction / Key Findings
- 4.6.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
- 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
  - 4.6.3.1. Hospital Pharmacies
  - 4.6.3.2. Retail Pharmacies
  - 4.6.3.3. Online Pharmacies
- 4.6.4. Market Attractiveness Analysis: Distribution Channel

5. Global Biobetters Market Outlook: Region

5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region

6. North America Biobetters Market Outlook:

6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 6.2.1. By Country
- 6.2.2. By Product Type
- 6.2.3. By Indication
- 6.2.4. By Route of Administration
- 6.2.5. By Distribution Channel
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 6.3.1. U.S.
- 6.3.2. Canada
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 6.4.1. Erythropoietin Biobetters
- 6.4.2. G-CSF Biobetters
- 6.4.3. Interferon Biobetters
- 6.4.4. Insulin Biobetters
- 6.4.5. Monoclonal Antibodies Biobetters
- 6.4.6. Anti-haemophilic Factor
- 6.4.7. Others
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 6.5.1. Diabetes
- 6.5.2. Cancer
- 6.5.3. Renal Disease
- 6.5.4. Neurodegenerative Disease
- 6.5.5. Genetic Disorders (Haemophilia)
- 6.5.6. Others
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 6.6.1. Subcutaneous
- 6.6.2. Intravenous
6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 6.7.1. Hospital Pharmacies
- 6.7.2. Retail Pharmacies
- 6.7.3. Online Pharmacies
6.8. Market Attractiveness Analysis

7. Europe Biobetters Market Outlook:

7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Product Type
- 7.2.3. By Indication
- 7.2.4. By Route of Administration
- 7.2.5. By Distribution Channel
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Turkey
- 7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 7.4.1. Erythropoietin Biobetters
- 7.4.2. G-CSF Biobetters
- 7.4.3. Interferon Biobetters
- 7.4.4. Insulin Biobetters
- 7.4.5. Monoclonal Antibodies Biobetters
- 7.4.6. Anti-haemophilic Factor
- 7.4.7. Others
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 7.5.1. Diabetes
- 7.5.2. Cancer
- 7.5.3. Renal Disease
- 7.5.4. Neurodegenerative Disease
- 7.5.5. Genetic Disorders (Haemophilia)
- 7.5.6. Others
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 7.6.1. Subcutaneous
- 7.6.2. Intravenous
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 7.7.1. Hospital Pharmacies
- 7.7.2. Retail Pharmacies
- 7.7.3. Online Pharmacies
7.8. Market Attractiveness Analysis

8. East Asia Biobetters Market Outlook:

8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Product Type
- 8.2.3. By Indication
- 8.2.4. By Route of Administration
- 8.2.5. By Distribution Channel
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 8.4.1. Erythropoietin Biobetters
- 8.4.2. G-CSF Biobetters
- 8.4.3. Interferon Biobetters
- 8.4.4. Insulin Biobetters
- 8.4.5. Monoclonal Antibodies Biobetters
- 8.4.6. Anti-haemophilic Factor
- 8.4.7. Others
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 8.5.1. Diabetes
- 8.5.2. Cancer
- 8.5.3. Renal Disease
- 8.5.4. Neurodegenerative Disease
- 8.5.5. Genetic Disorders (Haemophilia)
- 8.5.6. Others
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 8.6.1. Subcutaneous
- 8.6.2. Intravenous
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 8.7.1. Hospital Pharmacies
- 8.7.2. Retail Pharmacies
- 8.7.3. Online Pharmacies
8.8. Market Attractiveness Analysis

9. South Asia & Oceania Biobetters Market Outlook:

9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Product Type
- 9.2.3. By Indication
- 9.2.4. By Route of Administration
- 9.2.5. By Distribution Channel
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 9.4.1. Erythropoietin Biobetters
- 9.4.2. G-CSF Biobetters
- 9.4.3. Interferon Biobetters
- 9.4.4. Insulin Biobetters
- 9.4.5. Monoclonal Antibodies Biobetters
- 9.4.6. Anti-haemophilic Factor
- 9.4.7. Others
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 9.5.1. Diabetes
- 9.5.2. Cancer
- 9.5.3. Renal Disease
- 9.5.4. Neurodegenerative Disease
- 9.5.5. Genetic Disorders (Haemophilia)
- 9.5.6. Others
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 9.6.1. Subcutaneous
- 9.6.2. Intravenous
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 9.7.1. Hospital Pharmacies
- 9.7.2. Retail Pharmacies
- 9.7.3. Online Pharmacies
9.8. Market Attractiveness Analysis

10. Latin America Biobetters Market Outlook:

10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Product Type
- 10.2.3. By Indication
- 10.2.4. By Route of Administration
- 10.2.5. By Distribution Channel
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 10.4.1. Erythropoietin Biobetters
- 10.4.2. G-CSF Biobetters
- 10.4.3. Interferon Biobetters
- 10.4.4. Insulin Biobetters
- 10.4.5. Monoclonal Antibodies Biobetters
- 10.4.6. Anti-haemophilic Factor
- 10.4.7. Others
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 10.5.1. Diabetes
- 10.5.2. Cancer
- 10.5.3. Renal Disease
- 10.5.4. Neurodegenerative Disease
- 10.5.5. Genetic Disorders (Haemophilia)
- 10.5.6. Others
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 10.6.1. Subcutaneous
- 10.6.2. Intravenous
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 10.7.1. Hospital Pharmacies
- 10.7.2. Retail Pharmacies
- 10.7.3. Online Pharmacies
10.8. Market Attractiveness Analysis

11. Middle East & Africa Biobetters Market Outlook:

11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Product Type
- 11.2.3. By Indication
- 11.2.4. By Route of Administration
- 11.2.5. By Distribution Channel
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 11.4.1. Erythropoietin Biobetters
- 11.4.2. G-CSF Biobetters
- 11.4.3. Interferon Biobetters
- 11.4.4. Insulin Biobetters
- 11.4.5. Monoclonal Antibodies Biobetters
- 11.4.6. Anti-haemophilic Factor
- 11.4.7. Others
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 11.5.1. Diabetes
- 11.5.2. Cancer
- 11.5.3. Renal Disease
- 11.5.4. Neurodegenerative Disease
- 11.5.5. Genetic Disorders (Haemophilia)
- 11.5.6. Others
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 11.6.1. Subcutaneous
- 11.6.2. Intravenous
11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 11.7.1. Hospital Pharmacies
- 11.7.2. Retail Pharmacies
- 11.7.3. Online Pharmacies
11.8. Market Attractiveness Analysis

12. Competition Landscape

12.1. Market Share Analysis, 2025
12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Amgen Inc.
  - 12.3.1.1. Overview
  - 12.3.1.2. Segments and Products
  - 12.3.1.3. Key Financials
  - 12.3.1.4. Market Developments
  - 12.3.1.5. Market Strategy
- 12.3.2. F.Hoffmann-La Roche AG
- 12.3.3. Merck & Co. Inc.
- 12.3.4. Sanofi SA
- 12.3.5. SERVIER
- 12.3.6. Porton Biopharma Limited
- 12.3.7. Eli Lily and Company
- 12.3.8. Novo Nordisk A/S
- 12.3.9. Biogen Inc.
- 12.3.10. CSL Behring GmbH
- 12.3.11. Teva Pharmaceutical Industries Ltd.
- 12.3.12. Celltrion Healthcare Co., Ltd.

13. Appendix

13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations